Publications

Detailed Information

Comparison of 2 Different Paclitaxel-Coated Balloons in Coronary In-Stent Restenosis: A Randomized Controlled Trial

DC Field Value Language
dc.contributor.authorJun, Eun Jung-
dc.contributor.authorShin, Eun-Seok-
dc.contributor.authorYuan, Song Lin-
dc.contributor.authorBhak, Youngjune-
dc.contributor.authorGarg, Scot-
dc.contributor.authorKang, Woong Chol-
dc.contributor.authorKim, Je Sang-
dc.contributor.authorKim, June-Hong-
dc.contributor.authorBae, Jang-Whan-
dc.contributor.authorRha, Seung-Woon-
dc.contributor.authorChae, In-Ho-
dc.date.accessioned2022-09-30T05:54:19Z-
dc.date.available2022-09-30T05:54:19Z-
dc.date.created2022-08-18-
dc.date.issued2022-04-
dc.identifier.citationJACC: Asia, Vol.2 No.2, pp.170-179-
dc.identifier.issn2772-3747-
dc.identifier.urihttps://hdl.handle.net/10371/184994-
dc.description.abstract© 2022 The AuthorsBackground: Drug-coated balloons (DCBs) offer an effective treatment for in-stent restenosis (ISR). The Genoss DCB is a novel paclitaxel-coated balloon with a shellac plus vitamin E excipient that enhances drug delivery to the target lesion, minimizing restenosis. Objectives: This study aimed to investigate the angiographic efficacy, clinical safety, and effectiveness of the novel shellac plus vitamin E–based DCB in a randomized controlled trial designed to enable regulatory approval of this new device in South Korea. Methods: This noninferiority trial randomized patients experiencing their first ISR to the novel shellac plus vitamin E–based DCB or the reference SeQuent Please iopromide-based DCB in a 1:1 ratio. All patients underwent planned angiographic and clinical follow-up at 6 months. The study was powered for the primary endpoint of 6 months in-segment late lumen loss (LLL). Results: A total of 82 patients from 7 centers were randomized to either the novel shellac plus vitamin E–based DCB group (n = 41) or the reference iopromide-based DCB group (n = 41). The 6-month in-segment LLL was 0.15 ± 0.43 mm with the novel DCB compared with 0.24 ± 0.39 mm with the reference device. The 1-sided 97.5% upper confidence limit of the difference was 0.13 mm, lower than the noninferiority limit of 0.29 mm, achieving noninferiority (P for noninferiority = 0.001). Major cardiovascular events were comparable between 2 groups at 6 months (7.7% for the novel DCB vs 10.3% for the reference DCB; P = 0.692). Conclusions: In this multicenter, head-to-head comparison randomized trial, the novel shellac plus vitamin E–based DCB showed a comparable result to the reference iopromide-based device for the primary endpoint of 6-month in-segment LLL for the treatment of coronary ISR. (Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please in Korean Patient With Coronary In-stent Restenosis; NCT04405063)-
dc.language영어-
dc.publisherElsevier-
dc.titleComparison of 2 Different Paclitaxel-Coated Balloons in Coronary In-Stent Restenosis: A Randomized Controlled Trial-
dc.typeArticle-
dc.identifier.doi10.1016/j.jacasi.2021.11.015-
dc.citation.journaltitleJACC: Asia-
dc.identifier.scopusid2-s2.0-85132193295-
dc.citation.endpage179-
dc.citation.number2-
dc.citation.startpage170-
dc.citation.volume2-
dc.description.isOpenAccessN-
dc.contributor.affiliatedAuthorChae, In-Ho-
dc.type.docTypeArticle-
dc.description.journalClass1-
Appears in Collections:
Files in This Item:
There are no files associated with this item.

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share